Lexaria Bioscience Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lexaria Bioscience (LEXX).

Price Target Range — 6 Quarters

Analyst Consensus — 2 Analysts

2Buy

Consensus RatingBuy# Analysts2Avg. Consensus PT$101Upside to Avg. PT+2958.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Dec 26, 2025	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$60→$23
Jul 29, 2025	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$75→$60
Jul 1, 2025	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$105→$75
Jan 24, 2025	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$150→$105
Dec 2, 2024	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$150
Nov 25, 2024	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$150
Jul 18, 2024	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$150
Jul 10, 2024	HC Wainwright & Co.	Yi Chen	Initiate	Buy	$150
Mar 5, 2024	Maxim Group	Michael Okunewitch	PT Raise	Buy	$45→$180

Analyst Ratings News

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5

HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target from $4 to $1.5.

Benzinga Newsdesk

PRO
Watching Lexaria Bioscience; Zacks Small-Cap Research Gives Stock $8 Price Valuation

https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_07312025_LEXX_Vandermosten.pdf

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $4

HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target from $5 to $4.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $5

HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target from $7 to $5.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $7

HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target from $10 to $7.

Benzinga Newsdesk

Lexaria Bioscience Corp

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Lexaria Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5

PRO
Watching Lexaria Bioscience; Zacks Small-Cap Research Gives Stock $8 Price Valuation

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $4

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $5

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $7

People Also Watch

People Also Watch

Lexaria Bioscience Corp

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Lexaria Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday

PROHC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5

PROWatching Lexaria Bioscience; Zacks Small-Cap Research Gives Stock $8 Price Valuation

PROHC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $4

PROHC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $5

PROHC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $7

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5

PRO
Watching Lexaria Bioscience; Zacks Small-Cap Research Gives Stock $8 Price Valuation

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $4

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $5

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $7